Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria
- PMID: 2757528
- DOI: 10.1001/archneur.1989.00520440064022
Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria
Abstract
Over a 10-year period, we followed up 60 patients (35 men and 25 women) with chronic inflammatory demyelinating polyradiculoneuropathy. Diagnosis was based on previously outlined criteria. Patients were treated in a uniform manner and the overwhelming majority, 56 (94.9%) of 59 treated patients, initially responded to immunosuppressive therapy. The time for initial improvement was 1.9 +/- 3.6 months while the time to reach a clinical plateau was 6.6 +/- 5.4 months. The course was monophasic in 32 patients (53.3%) and relapsing in 28 (46.6%). Despite the initial responsiveness, only 24 (40%) of 60 patients are in partial or complete remission, receiving no medication. Two patients died. We were unable to identify specific clinical or laboratory features at the time of diagnosis that predicted outcome. Our data analysis, along with previous reports, suggests that chronic inflammatory demyelinating polyradiculoneuropathy may be more heterogeneous than previously emphasized. In this light, we have proposed diagnostic criteria that allow for the heterogeneity but at the same time provide for a more consistent approach to better establish the natural history of this condition.
Similar articles
-
Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases.Brain. 1987 Dec;110 ( Pt 6):1617-30. doi: 10.1093/brain/110.6.1617. Brain. 1987. PMID: 3427403
-
[Double filtration plasmapheresis (DFPP) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)].Rinsho Shinkeigaku. 1998 Aug;38(8):719-23. Rinsho Shinkeigaku. 1998. PMID: 9916516 Clinical Trial. Japanese.
-
Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood.J Neurol Sci. 1998 Jan 21;154(1):66-71. doi: 10.1016/s0022-510x(97)00216-5. J Neurol Sci. 1998. PMID: 9543324
-
Chronic inflammatory demyelinating polyradiculoneuropathy.Annu Rev Med. 1993;44:211-9. doi: 10.1146/annurev.me.44.020193.001235. Annu Rev Med. 1993. PMID: 8476243 Review.
-
Electrophysiology of the inflammatory demyelinating polyneuropathies.Baillieres Clin Neurol. 1994 Apr;3(1):25-43. Baillieres Clin Neurol. 1994. PMID: 7921590 Review. No abstract available.
Cited by
-
Clinical efficacy of high-dose intravenous gammaglobulin in acute Guillain-Barre syndrome and effect on serum concentration of inflammatory factors.Am J Transl Res. 2022 Sep 15;14(9):6295-6302. eCollection 2022. Am J Transl Res. 2022. PMID: 36247287 Free PMC article.
-
Hepatocellular carcinoma presenting with chronic inflammatory demyelinating polyradiculoneuropathy.Dig Dis Sci. 2000 Dec;45(12):2369-73. doi: 10.1023/a:1005690908999. Dig Dis Sci. 2000. PMID: 11258560 No abstract available.
-
Chronic Inflammatory Demyelinating Polyneuropathy Post-mRNA-1273 Vaccination.Cureus. 2022 Apr 27;14(4):e24528. doi: 10.7759/cureus.24528. eCollection 2022 Apr. Cureus. 2022. PMID: 35651399 Free PMC article.
-
Sensory neuropathies including painful and toxic neuropathies.J Neurol. 1997 Apr;244(4):209-21. doi: 10.1007/s004150050075. J Neurol. 1997. PMID: 9112589 Review.
-
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD002062. doi: 10.1002/14651858.CD002062.pub4. Cochrane Database Syst Rev. 2017. PMID: 29185258 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources